PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 14th Israel Controlled Release Society (ICRS) Conference. The company's Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs, Dalit Hazan, will deliver a presentation titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" on September 7, 2025.

The presentation is scheduled for 5:25 PM - 5:45 PM local time at the Enjoy Hotel, Dead Sea, Israel, as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025.

The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on Sunday, September 7, 2025, from 5:25 PM - 5:45 PM local time as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,  PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd. 
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
polypid@arxadvisory.com

FAQ

When and where will PolyPid (PYPD) present at the ICRS Conference 2025?

PolyPid will present on September 7, 2025, from 5:25 PM to 5:45 PM local time at the Enjoy Hotel, Dead Sea, Israel.

Who will be presenting for PolyPid at the ICRS Conference 2025?

Dalit Hazan, Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs at PolyPid, will be presenting.

What is the topic of PolyPid's presentation at the ICRS Conference?

The presentation is titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" and will be part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."

What is PolyPid's (PYPD) main business focus?

PolyPid is a late-stage biopharma company focused on improving surgical outcomes through their drug delivery technology.